Share ownership Arrowhead Pharmaceuticals, Inc.

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2025 BST			5-day change	1st Jan Change
18.86 ^USD	-0.11%		+12.33%	+0.32%

07-08	Arrowhead Pharmaceuticals, Inc., Q2 2025 Earnings Call, May 12, 2025
07-08	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	CI

Share class: Arrowhead Pharmaceuticals, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	126,098,111	118,882,205 ( 94.28 %)	0	94.28 %

Major shareholders: Arrowhead Pharmaceuticals, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 15.11 %	19,054,486	15.11 %	301 M $
Vanguard Fiduciary Trust Co. 10.47 %	13,202,562	10.47 %	209 M $
SAREPTA THERAPEUTICS, INC. 9.458 %	11,926,301	9.458 %	188 M $
Avoro Capital Advisor LLC 8.811 %	11,111,111	8.811 %	176 M $
STATE STREET CORPORATION 5.551 %	6,999,249	5.551 %	111 M $
Slate Path Capital LP 4.149 %	5,232,000	4.149 %	83 M $
UBS Asset Management (UK) Ltd. 3.795 %	4,785,062	3.795 %	76 M $
Christopher Anzalone 3.11 %	3,921,255	3.11 %	62 M $
Fidelity Management & Research Co. LLC 2.629 %	3,315,082	2.629 %	52 M $
Geode Capital Management LLC 2.34 %	2,950,312	2.34 %	47 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	75%
Sarepta Therapeutics, Inc.	9.46%
State Street Corp.	5.55%
Other	4.94%
Individuals	4.8%
Silvercrest Asset Management Group, Inc.	0.22%
Schweizerische Nationalbank	0.17%
SEI Investments Co.	0.05%
Manulife Financial Corp.	0.05%
Corebridge Financial, Inc.	0.05%
Governments	0.04%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	84.51%
United Kingdom	6.08%
Individuals	4.8%
Norway	1.65%
Switzerland	1.01%
Canada	0.57%
Netherlands	0.5%
France	0.24%
Israel	0.22%
China	0.16%
Denmark	0.11%
Ireland	0.1%
Sweden	0.09%
Australia	0.08%
Japan	0.06%
Austria	0.04%
Germany	0.04%
Singapore	0.02%
Luxembourg	0.02%
Czech Republic	0.01%
Cayman Islands	0.01%
Belgium	0.01%

Based on 1000 largest holdings

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

609

Sector

Biotechnology & Medical Research

Calendar

08-10 - Q3 2025 Earnings Release (Projected)

More about the company